Podcasts about MDS

In this episode, we dive deep into ASH 2025 updates on myeloid malignancies with Dr. Curtis Lachowiez. From the plenary halls of ASH 2025 to long-term follow-up of Aza/Ven/Gilteritinib, we unpack what the latest evidence means for the future of AML management.1. PARADIGM Trial (Plenary Session, Abstract 6)Fathi A, Perl A, Fell G, et al. Results from PARADIGM – a phase 2 randomized multi-center study comparing azacitidine and venetoclax to conventional induction chemotherapy for newly diagnosed fit adults with acute myeloid leukemia. Blood 2025;146(Suppl 1):6.https://doi.org/10.1182/blood-2025-6ClinicalTrials.gov: NCT048017972. VICEROY Study – Aza/Ven/Gilteritinib Triplet (Abstract 654)Venetoclax (VEN) and azacitidine (AZA) with gilteritinib (GILT) in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy: Interim results from the phase 1/2 VICEROY study. Blood 2025;146(Suppl 1):654.ClinicalTrials.gov: NCT055205673. Long-Term Follow-Up of Aza/Ven/Gilteritinib in FLT3-Mutated AML (Abstract 45)Azevedo RS, et al. Long-term follow-up of azacitidine, venetoclax, and gilteritinib in patients with newly diagnosed FLT3-mutated acute myeloid leukemia. Blood 2025;146(Suppl 1):45.Original publication: Short NJ, Daver N, DiNardo CD, et al. J Clin Oncol 2024;42:1499–1508. https://doi.org/10.1200/JCO.23.01911ClinicalTrials.gov: NCT041404874. PRISM-AML Score (Abstract 453)Lachowiez CA, et al. Prognostic risk integration for survival modeling (PRISM) in newly diagnosed acute myeloid leukemia treated with venetoclax: A multinational retrospective cohort study. Blood 2025;146(Suppl 1):453.Interactive Calculator: https://prism-aml.com5. Additional Studies Referenced in Discussion•       VIALE-A Trial: DiNardo CD, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 2020;383:617–629. (NCT02993523)•       VERONA Trial: Randomized study of Aza-Ven vs. Aza vs. placebo in MDS (discussed as a negative study)•       4-Gene Classifier (mPRS): Bataller A, et al. Prognostic risk signature in patients with AML treated with HMA and venetoclax. Blood Adv 2024;8(4):927–935. https://doi.org/10.1182/bloodadvances.2023011757•       LACEWING Trial: Azacitidine plus gilteritinib vs. azacitidine plus placebo in FLT3-mutated AML (discussed as a negative study) 

This is the first episode in a three-part series I'm calling Dr. Ospina Explains. In this series, we'll dive into topics many of you have been asking about recently. One of my favorite Movement Disorder Specialists, Dr. Ospina, has a wonderful way of explaining all things Parkinson's in terms that are easy for the rest of us to understand. I hope you'll tune in to all three parts as they're released — I truly believe you'll learn a lot. We're starting with Botox. Like many people, I used to think Botox had only one purpose — cosmetic. But after speaking with Movement Disorder Specialist Dr. Marie Ospina, I learned that Botox can actually help treat several symptoms that occur in people living with Parkinson's. You'll discover exactly what those symptoms are when you listen to my conversation with Dr. Ospina. I think you may be surprised — and you might even find yourself asking your MDS or neurologist whether Botox could help relieve some of your pain or muscle tightness. Stay tuned! Thank you to our sponsor – Boston Scientific, the maker of Vercise Genus, a Deep Brain Stimulation or DBS system. To learn more about the latest treatment options for Parkinson's disease at https://DBSandMe.com/17branches   

On nous avait promis l'apocalypse, on a eu une leçon de force. Ce matin, le marché respire après le verdict du King de l'IA et une résilience surprenante des actifs à risque.Au programme de ce débrief :NVIDIA (L'Intouchable) : $67 Mds de CA, des marges indécentes et un carnet de commandes Blackwell plein jusqu'en 2027. On analyse pourquoi Jensen Huang vient de balayer d'un revers de main toutes les craintes de bulle.CRYPTO (The Undead) : Pour tous ceux qui ont enterré le Bitcoin et l'Ether trop vite : désolé, mais le rebond est là. On décortique pourquoi la liquidité revient et pourquoi la "mort" des cryptos n'était qu'une fake news de plus.TRUMP & TAXES : La Section 122 est activée, les 15% de taxes sont là. Comment le marché encaisse-t-il ce choc protectionniste sans flancher ?PSYCHO : Pourquoi la réussite, c'est savoir rester dans le train quand tout le monde veut sauter. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Bienvenue dans votre shot d'adrénaline financière. Ce matin, on est au cœur de la tempête. Entre un Président qui joue avec les nerfs de la Cour Suprême et une boîte qui porte à elle seule le poids du futur technologique, il n'y a pas de place pour le doute.Au programme ce matin :NVIDIA (Le Juge de Paix) : À 22h05, Jensen Huang va parler. $66 Mds de CA attendus. Le "Blackwell" est-il le sauveur du Nasdaq ou le premier signe d'un essoufflement ? On décortique les attentes.TRUMP SOTU : 1h48 de discours pour graver les 15% de taxes dans le marbre. On analyse la Section 122 du Trade Act et pourquoi la guerre douanière est désormais une réalité comptable pour vos portefeuilles.GENÈVE & PÉTROLE : À la veille de la réunion cruciale avec l'Iran, le pétrole est en apnée. Diplomatie ou capitulation ? On fait le point sur la prime de risque.PSYCHO & VALEURS : La Rolex à 50 ans ? On démonte ce cliché poussiéreux. Pourquoi la vraie réussite n'est pas dans l'avoir, mais dans l'être, l'intégrité et la transmission. Hébergé par Acast. Visitez acast.com/privacy pour plus d'informations.

Proactive Care Is a Pathway — Not a SloganPT is built for prevention.But most of healthcare still waits until pain shows up.In this episode recorded live at CSM in Anaheim, Dr. Tatiana Olevsky discusses:Why patients still go to MDs first for MSK painThe public awareness gap around direct accessHow PTs can shift from reactive rehab to proactive performanceWhy outcomes — not visit counts — should define our valueLessons from Pilates and community-buildingMovement analysis as a preventative toolWhy PT is at an inflection pointKey TakeawaysPrioritize quality over quantityScreen upstream before pain becomes diagnosisBuild rapport before educationShow patients the future, don't just prescribe sets and repsIf PT wants to be first-line, we must earn itGuest InfoDr. Tatiana Olevsky Spine PT Fellow | Private Practice Owner | Educator

Guest: Dr. Rachel Zoffness – Pain Psychologist | UCSF + Stanford Faculty | Author of Tell Me Where It HurtsTopic: Revolutionizing Pain Education and TreatmentWhat You'll Learn in This Episode:Why the brain—not the body—is the control center for painHow chronic pain can be managed and treated (not just medicated)Real case study: “Sam” and the power of biopsychosocial careWhy PTs, MDs, and psychologists must collaborateWhy medical education fails to teach modern pain scienceHow you can create your own “pain recipe” for better outcomesBehind the scenes of Rachel's new book, publishing journey & outreachLinks + Resources???? Website: zoffness.com???? Book: Tell Me Where It Hurts — Order Now???? Follow: @TheRealDocZoff, @drzoffness???? Want Rachel to record your voicemail? Preorder and submit at zoffness.com

At the 2026 Tandem Meetings, CancerNetwork® spoke with a variety of experts who presented on key developments and advancements across hematologic oncology. As part of different oral presentations and poster sessions, researchers and clinicians shared updated findings that may influence the management of myelodysplastic syndromes (MDS), leukemia, lymphoma, and other blood cancer types.First, Fernando Duarte, head of the Bone Marrow Transplant Service at Walter Cantídio University Hospital (HUWC), hematologist and professor at the Federal University of Ceará, and president of the Brazilian Society of Cell Therapy and Bone Marrow Transplant, highlighted his presentation analyzing trends associated with allogenic hematopoietic cell transplantation (allo-HCT) among patients with MDS or myeloproliferative neoplasms (MPN) and other types of MDS. Data from the Brazillian SBTMO and CIBMTR registry revealed that patients receiving allo-HCT for MDS/MPN were typically older with worse performance statuses. Additionally, MDS/MPN independently predicted worse overall survival (OS) and relapse-free survival outcomes.Next, Alfonso Molina, MD, MPH, a third-year Hematology and Medical Oncology fellow at Stanford University, detailed results from a phase 1 trial (NCT05507827) assessing Orca-T, an investigational allogeneic T-cell immunotherapy, among those with high-risk B-cell acute lymphoblastic leukemia (B-ALL). Treatment with Orca-T yielded disease-free survival and OS in all (100%) 18 evaluable patients after a median follow-up of 14 months (range, 3-35), which occurred without graft failure, significant graft-versus-host-disease, or severe CAR-mediated toxicity.Finally, Irtiza N. Sheikh, DO, an assistant professor in the Department of Pediatrics - Patient Care, Stem Cell Transplantation and Cellular Therapy Section of the Division of Pediatrics at The University of Texas MD Anderson Cancer Center, discussed his presentation exploring differences in outcomes with lisocabtagene maraleucel (Breyanzi; liso-cel) across various treatment settings and patient populations with large B-cell lymphoma. Data demonstrated that among patients younger than 50 years old, liso-cel produced enduring responses across real-world and clinical trial settings, which were comparable to outcomes in overall populations. References Duarte FB, Garcia YDO, Hamerschlak N, et al. Comparative outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and other myelodysplastic syndromes: Brazilian Sbtmo/CIBMTR registry analysis. Presented at: 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 4-7, 2026; Salt Lake City, UT. Presentation 63. Molina A, Shiraz A, Kanegai A, et al. Mature outcomes from the phase I trial of Orca-T and allogeneic CD19/CD22 CAR-T cells for adults with high-risk B-ALL. Presented at: 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 4-7, 2026; Salt Lake City, UT. Presentation 31. Sheikh IN, Patel K, Perales MA, et al. Clinical outcomes of lisocabtagene maraleucel (liso-cel) in YOUNGER PATIENTS (Pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). Presented at: 2026 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR; February 4-7, 2026; Salt Lake City, UT. Poster 210.

A $400 million exit and a reputational reckoning in wellness put this episode of Taste Radio on edge, as the team dissects Bachan's blockbuster acquisition and the fallout facing brands tied to wellness guru Peter Attia. The conversation also spotlights Solely's growth strategy in an interview with Manish Amin, VP of marketing for the fast-growing organic fruit snack brand. Show notes: 0:23: Many Meetups. Marzetti's Move. Attia Outta Here. Will Shat? DKB, MDS, MHH. – The hosts preview Taste Radio's packed year of networking events and live podcast meetups, kicking off in Miami. The hosts turn their attention to Marzetti's $400 million acquisition of Bachan's, examining how the Japanese barbecue sauce brand emerged as a standout CPG success story. They also dive into tougher conversations around reputational risk following recent revelations involving wellness influencer Peter Attia. Ray teases a surprising celebrity partnership between William Shatner and Raisin Bran, before the hosts spotlight new products from Dave's Killer Bread, Mid-Day Squares, Tama Tea, Tart Beverages, and Mike's Hot Honey Syrup. 28:16: Interview: Manish Amin, VP of Marketing, Solely – Ray sits down with Manish at the recent Naturally San Diego event to discuss Solely's mission and product lineup. Manish shares the brand's focus and positioning, emphasizing a commitment to genuinely good-for-you, great-tasting products. He also highlights Solely's role in pushing the broader snack industry toward cleaner labels and better ingredients. Brands in this episode: Solely, Bachan's, Marzetti, Olive Garden, Chick-fil-A, Buffalo Wild Wings, Arby's, Subway, Texas Roadhouse, New York Bakery, Sister Schubert's, AG1, Magic Spoon, LMNT, David Protein, Kellogg's Raisin Bran, Smart Bran, Dave's Killer Bread, Mid-Day Squares, Tama Tea, Tart, Mike's Hot Honey, Jolly Rancher, Red Hots, Absolut Vodka, Tabasco

Le réveil pique ce matin sur la Tech. Hier, on a eu la preuve par l'image : faire de la croissance, c'est bien, mais la payer au prix fort, le marché déteste ça. Entre Alphabet et Amazon qui annoncent des dépenses d'investissement (CapEx) lunaires pour 2026 (on parle de près de 400 Mds$ cumulés !), les investisseurs ont tranché : ils vendent la news.

1. Le séisme Novo Nordisk

We are joined by Crystal Clark, who has completed the MDS, a 250km stage race, self supported and various other ultras!  She is now coaching and shares her adventures and outlook on running.  Schuyler Hall fills in for Brother Bill, who is under the weather.. 

When people hear “forensic accountant” during divorce, expectations run high. Many assume it means hidden money will automatically be uncovered or that every financial mystery will be solved. The reality is more nuanced—and far more strategic. In this episode, we sit down with Sara Nanchanatt, founder of SN Forensics, to demystify what forensic accounting actually does in divorce, when it's worth the investment, and when it's not. Sara brings clarity to one of the most misunderstood (and expensive) parts of the divorce process—helping listeners understand how to make informed, cost-effective decisions instead of emotionally driven ones. This conversation is especially important if you're navigating a divorce involving business ownership, complex finances, cash-based income, or concerns about missing information. What We Cover in This Episode What a forensic accountant really does in divorce—and what they can't do Why not every divorce requires forensic accounting How attorneys often default to “we need a forensic” (and why that matters) When business valuations make financial sense—and when they don't The red flags forensic accountants actually look for Why “cash businesses” and “hidden assets” aren't always traceable The difference between consulting, expert witness, and rebuttal roles How limited-scope forensic work can save thousands What questions to ask before hiring a forensic accountant How preparation and document review can prevent wasted legal and expert fees Key Takeaways for Listeners ✔️ Forensic accounting is a tool, not a guarantee ✔️ Spending money without a clear scope often leads to frustration and disappointment ✔️ The goal isn't to “prove wrongdoing”—it's to understand the numbers well enough to make informed decisions ✔️ Preparation before engaging experts can dramatically reduce costs ✔️ A strong divorce team communicates clearly and works collaboratively Why This Conversation Matters Divorce already brings emotional overload. Adding unnecessary experts—without understanding the likely outcome—can escalate costs and stress without improving results. This episode reinforces a core MDS belief: Fear is expensive. Clarity is not. Understanding when forensic accounting adds value—and when it doesn't—puts control back where it belongs: with you. About Our Guest Sara Nanchanatt is a forensic accountant and business valuation expert with experience spanning Charles River Associates, FINRA, and complex financial investigations across multiple industries. Through SN Forensics, she works with individuals and divorce teams to uncover financial truth while prioritizing efficiency, transparency, and realistic outcomes.

NDC announces sweeping reforms as part of a major reorganization drive. The party has directed all members occupying government offices—Ministers, Deputies, CEOs, and MDs of state institutions—who intend to contest any party position to resign six months ahead of the 2026 internal elections.

Mikkael A. Sekeres, MD, MS Curious about what's new in the world of myelodysplastic syndromes (MDS)? We're bringing you the latest insights straight from one of the field's leading experts. In this episode, we speak with Dr. Mikkael Sekeres, of the Sylvester Comprehensive Cancer Center at University of Miami Health. Recorded onsite at the 2025 ASH (American Society of Hematology) Annual Meeting and Exposition, this conversation explores what MDS is, how it's treated today, and what researchers are learning about managing side effects. Dr. Sekeres also walks us through the most notable MDS updates presented at ASH, highlighting promising therapies and clinical trial data that may help shape future care. Whether you're newly learning about MDS or following ongoing research, this episode offers an accessible look at where things stand and what's on the horizon. *This is not an official program of the ASH annual meeting DOWNLOAD TRANSCRIPT CLICK HERE to participate in our episode survey. Mentioned on this episode: Myelodysplastic syndromes International Prognostic Scoring System for MDS American Society of Hematology Highlights from ASH vlog Blood cancer research 2026: Meeting patients where they want to be | blog post Additional Blood Cancer United Support Resources: Free Nutrition Consultations Information Specialists Financial support Clinical Trial Support Center Online Chat Free telephone/web patient programs Free booklets Young Adult Resources Support groups Caregiver support Caregiver Workbook Survivorship Workbook Advocacy and Public Policy Patient Community Mental Health Resources Episode supported by Geron Corporation and Taiho Oncology, Inc.The post The Bloodline Live! Myelodysplastic Syndromes (MDS) Updates in Research first appeared on The Bloodline with Blood Cancer United Podcast.

The buzz is real when it comes to Des's trail plans for this year. She just announced her first trail race of the season - the Black Canyon 50K - on February 15th in prep for the epic stage race Marathon des Sables (MDS) in April. MDS is a self-supported, multi-stage ultramarathon, primarily held in the Moroccan Sahara, where runners cover ~250 km (155 miles) in six days, carrying all their own food and gear while facing desert conditions, and sleeping in communal tents with other participants. We know Des likes a sufferfest, so it shouldn't be surprising that this race has captured her attention. She gives a little preview of her prep and opens the floor for some help for her team name. Drop your ideas in the YouTube or Spotify comments! Then, Des and Kara talk about the impending choice for the host city of the 2028 Olympic Marathon Trials. Phoenix and St. Louis go head-to-head for the opportunity to choose our Olympic marathoners for LA. What factors should be considered and which city might have the edge? Finally (before a Top 5), they preview the indoor track action coming up at the NB Indoor Games and at Millrose. There are some fun and exciting races to watch in the coming weekends, and they give you some tips on what and who to watch! Track is back! Thank you to Lagoon Sleep for sponsoring this podcast. Take the quiz to find your ideal pillow and use code NOBODYASKEDUS for 15% off at LagoonSleep.com/NOBODYASKEDUS.

When it comes to working in military intelligence, strong leadership skills and the ability to make quick decisions under pressure are key. Just as important to a mission's success is being a good team player.Those were the lessons and skills Chris Stillwell '24 carried into his two career pivots after his time working as a military intelligence officer for the U.S. Army. His first pivot landed him a role at Kearney in Dubai focusing on M&A integration and strategy consulting. Chris then decided to pursue an MBA at Rice Business to sharpen his financial skills and pivot once again into the world of investment banking. Now an investment banking associate at Bank of America, Chris joins co-host Brian Jackson '21 to discuss his military experience, why he chose Rice, how the program helped him make a major career transition, and his advice to those considering an MBA to pursue new career opportunities. Episode Guide:00:00 Introduction to Chris Stillwell01:03 Military Intelligence: Separating Fact From Fiction02:15 Roles and Responsibilities in the Army03:08 Leadership and Decision Making in High-Pressure Situations08:07 From Military to Consulting09:49 Living Abroad: Challenges and Cultural Insights15:02 Transitioning to an MBA at Rice University18:13 Involvement and Networking at Rice20:56 Entering Investment Banking: Preparation and Challenges25:37 Day-to-Day in Investment Banking28:46 Advice for Career Pivoters and VeteransThe Owl Have You Know Podcast is a production of Rice Business and is produced by University FM.Episode Quotes:The moment Chris realized that Rice gave him an edge over his peers[20:48] Brian: Going into investment banking, was there, like, now an elevated sense of confidence of, Okay, I've done this before; I'll do it again?[20:56] Chris: Maybe some blind confidence sometimes. Yeah, you could even ask my parents. I went home for like four days for the Christmas break the year I was recruiting. And I was studying flashcards with my mom of all the IB 400 questions. And I was like, “I'm not going to get a job. You know, like all these people around me are much smarter than me. There's a really—we've got a really talented pool of candidates that are recruiting this year.” But you know, I felt like at the end of the day, the Finance Association and Rice, just the classes I took, really prepared me to understand the basics of finance, the basics that are expected of the interview process. And then, going forward, I saw when I started as an intern at the bank, I went to New York for a week…We were training with all these people from all these different schools, going to all these different groups in the bank, and some people didn't even know what a DCF was or didn't know how to do it that well, I should say. We were doing some practice problems, and I was like, “Wow, we're actually far ahead of a lot of these other schools and people.” So that was kind of good to see that Rice really put an effort into training us up. What Chris learned about leadership through three career pivots[30:15] There are certain people who can be leaders and are very good at being leaders. But being a good leader in the military might not translate to being a good leader at banking. And a lot of times you actually see that, or you see military officers leave the military and go into the corporate world and not be as successful. Because I really think you do need to tailor your leadership style to the one the industry you're working in, and two, the people you're working with, you know, different ways of operating motivate people differently. Like in the military, you could yell at somebody and hold them to a higher standard and maybe they'll do it. But if you yelled at somebody like, you know, a marketing job, they probably would shut down and that'd be the end of it. It really doesn't work the same. The leadership style is something that you have to adjust to the area you're working in.On how his military experience strengthened his teamwork skills[04:03] In the military, you are a leader, but you learn how to be a good follower as well. And I think what you do with that is that you are able to have great teamwork. You're able, like in my current job now, I have an analyst underneath me, but I have people like VPs and MDs above me and I can understand what their intent is and what we need to get accomplished in our day-to-day job, but also articulate to the people below me, Hey, this is the intent and this is how we do it. So it's kind of been very helpful in those soft skills.On how Rice gave him the academic foundation he needed[16:49] My reasons for going to Rice were great, but once I got there, I appreciated it a lot more. I really got exposed to, I mean, I was looking for some things like smaller classrooms for example. Like a lot of people we hire from Kearney were from Yale or HBS, and their class size was like a thousand people. And maybe you didn't have a lot of rigor in terms of academics. I think Rice, especially in the first term, really forces you to go to classes to do your homework, to learn the materials. And that was attractive to me as well, because I didn't come from a finance background at all. So I didn't even know what a DCF was before I came to Rice. So I was very grateful at that, you know, getting to Rice and realizing that it was such a good platform to be integrated into.Show Links: TranscriptGuest Profile:Chris Stillwell | LinkedIn

In today's episode, the discussion features Guillermo Garcia-Manero, MD, who reviewed the clinical rationale for targeting BCL-2 in higher-risk myelodysplastic syndrome (MDS) and outlined the phase 3 GLORA-4 trial (NCT06641414) evaluating lisaftoclax (APG-2575) plus azacitidine (Vidaza) in this population. Dr Garcia-Manero is the chair ad interim in the Department of Leukemia in the Division of Cancer Medicine, as well as leader of the MDS/AML Moon Shot Program, at The University of Texas MD Anderson Cancer Center in Houston.In the exclusive interview, Dr Garcia-Manero contextualized lisaftoclax as a next-generation BCL-2 inhibitor being advanced as a hypomethylating agent (HMA) partner strategy intended to improve on outcomes historically achieved with azacitidine alone in higher-risk MDS. He emphasized that GLORA-4 is designed as a registrational, randomized trial to rigorously assess whether adding BCL-2 inhibition to standard HMAs can meaningfully deepen responses and translate into clinically relevant benefit. He also characterized the regimen's tolerability profile in a population that often requires careful supportive care and dose management.

Please visit answersincme.com/860/99519635-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Guillermo Garcia-Manero, MD and John Mascarenhas, MD. In this activity, experts in Myelodysplastic Syndromes discuss the latest data for the treatment of anemia in patients with MDS and myelofibrosis. Upon completion of this activity, participants should be better able to: Discuss the latest data for the treatment of anemia in patients with myelodysplastic syndromes (MDS) and myelofibrosis (MF); and Translate the latest data into real-world treatment plans for the treatment of anemia.

F2 is the AI platform for private markets investors, automating due diligence and portfolio monitoring workflows with agentic AI. After building ARK into a digital banking platform that scaled from tens of millions to tens of billions in loan volume, Donald Muir developed AI technology to automate debt placement on ARK's marketplace. When upmarket institutional lenders requested access to the AI for their entire deal flow—not just ARK's marketplace deals—Donald recognized the technology's standalone value. In this episode of BUILDERS, Donald shares how he's commercializing enterprise-grade AI for an industry where he personally spent years in the private equity bullpen, and how F2 is addressing the reliability and trust barriers that prevent AI adoption in high-stakes financial decision-making. Topics Discussed How F2 emerged from ARK's internal need to automate debt marketplace screening memos The technical approach to eliminating hallucination in Excel-based financial analysis Replicating private equity's "super day" interview format to prove AI capability with live deal data Sales team composition: hiring ex-finance professionals instead of traditional sales reps AI's role in evolving private equity analysts from menial tasks to system operators Product roadmap from due diligence to portfolio monitoring to deal syndication platform Maintaining operational independence while preserving strategic alignment with ARK GTM Lessons For B2B Founders Solve your own hardest problem first, then productize: Donald built F2's core technology to scale ARK's debt marketplace, focusing on the most difficult engineering challenge—reliable financial analysis of unstructured Excel data—because the marketplace required it. This resulted in technology that foundation models still haven't replicated over a year later. The aha moment came when institutional lenders wanted the AI for all their deal flow, not just marketplace transactions. Organic internal development created category-leading capabilities and validated product-market fit before commercialization. B2B founders should identify which internal operational challenges, if solved, could become standalone products serving the broader market. Design sales processes that mirror how your ICP evaluates talent: Donald replicated private equity's "super day" format where analyst candidates receive a data room, laptop without internet access, and three hours to produce an LBO model and investment thesis. F2 runs identical timed tests—customers send live deal data rooms under NDA, F2 generates investment committee memos using their templates, and presents same-day results. This proves the AI can perform at the standard funds use to evaluate human analysts they hire 18 months before start dates. B2B founders selling into industries with rigorous talent evaluation processes should reverse-engineer those frameworks into product demonstrations that speak to buyer expectations. Prioritize credibility over sales experience in technical markets: Donald's entire sales team consists of ex-finance professionals who lived in the seat—no traditional salespeople. These reps can screen-share investment memos created that morning and discuss them authentically with MDs and principals using industry-specific language. After 4.5 years running go-to-market at ARK, Donald teaches sales methodology to domain experts rather than teaching domain expertise to salespeople. For deals averaging half a billion dollars flowing through the platform, buyer credibility outweighs sales polish. B2B founders in specialized verticals should evaluate whether domain fluency or sales pedigree matters more for their specific buyer personas and deal complexity. Engineer for auditability before optimizing for speed: F2 focused on eliminating hallucination and achieving mathematical accuracy—solving what Donald calls the "reliability and trust" gap—before addressing workflow efficiency. The company name references the F2 keystroke used to audit Excel calculations at 3 AM in the PE bullpen. This positioning directly addresses the barrier preventing AI adoption for investment decisions: LLMs hallucinate, can't do math, and lack auditability. Only after proving the AI produces auditable, trustworthy output did F2 layer on speed benefits. B2B founders building for high-stakes decision environments should identify the fundamental trust barrier and make it the core technical focus before feature expansion. Leverage institutional knowledge as competitive differentiation: Beyond automating existing workflows, F2 enables firms to pipe in decades of institutional knowledge via API—instantly benchmarking new deals against thousands of historical transactions by vertical, revenue size, leverage levels, and management quality. This transforms screening memos from isolated analyses into context-rich evaluations informed by complete firm history. The AI doesn't just work faster; it has comprehensive context that individual analysts manually searching SharePoint folders could never access. B2B founders should identify where accumulated institutional data creates compounding value beyond point-in-time automation. // Sponsors: Front Lines — We help B2B tech companies launch, manage, and grow podcasts that drive demand, awareness, and thought leadership. www.FrontLines.io The Global Talent Co. — We help tech startups find, vet, hire, pay, and retain amazing marketing talent that costs 50-70% less than the US & Europe. www.GlobalTalent.co // Don't Miss: New Podcast Series — How I Hire Senior GTM leaders share the tactical hiring frameworks they use to build winning revenue teams. Hosted by Andy Mowat, who scaled 4 unicorns from $10M to $100M+ ARR and launched Whispered to help executives find their next role. Subscribe here: https://open.spotify.com/show/53yCHlPfLSMFimtv0riPyM

Send us a textDr. Shauna Birdsall is a naturopathic doctor with over 25 years of experience in integrative oncology. She got her naturopathic medical degree in Oregon and then did her residency in oncology in Illinois. She later practiced in Arizona and then from there ventured to Alaska in 2019 where she practiced in several oncology practices along allopathic providers in the MatSu, Soldotna, and here in Anchorage. Allopathic medicine is the medicine that most of us think of as traditional medicine; MDs, DOs, nurse practitioners and physician assistants like myself are part of the allopathic medical tradition while naturopaths are an alternative medical tradition. But as you will hear from our guest today the two are not mutually exclusive. During the course of today's conversation we will reference House Bill 147 sponsored by Representative Mike Prax of North Pole. This legislation would grant Alaska naturopaths the ability to write prescriptions for certain allopathic medications, among other things.

A stronger primary care relationship can be the difference between constant crisis and steady health. That's the throughline of our conversation with Dr. Detwiler, the incoming Director of Osteopathic Medicine at the CMG Lynchburg Family Medicine Residency. Dr. Detwiler brings rural roots, 25 years of family practice and a clear mission, to train physicians who treat mind, body and spirit while delivering measurable results for communities that need care the most.We dig into what actually sets osteopathic medicine apart. It's not a split from modern medicine. DOs are fully trained in the same diagnostics, procedures and specialties as MDs. The distinction is a disciplined focus on human connection, structure and function and the body's capacity to heal with proper support. That lens changes the clinic room. Conversations include stress, sleep, work, beliefs and budget, because those factors drive adherence and outcomes. We also clear up misconceptions about OMT. Osteopathic manipulative treatment is a practical, hands-on tool for musculoskeletal issues, designed to complement medications and therapy, not replace them. At LFMR, we're building a curriculum that helps residents provide OMT efficiently within standard visits.There's a bigger system story too. Healthcare is shifting toward value-based care, where metrics like blood pressure control, A1C levels, and vaccination rates matter. LFMR's team-based model with residents, faculty, imaging, lab, OB care and social work under one roof makes it easier to close loops and lift those numbers. And the pipeline is real. By partnering with LUCOM and integrating trainees with local surgeons, hospitalists and specialists, we're creating the relationships that encourage physicians to stay at Centra for their care. That means more access, shorter waits and care that feels personal and effective.We're also launching an OMT clinic at LFMR for patients seeking targeted help with back and musculoskeletal pain from an osteopathic perspective. If you've struggled to find a primary care provider who listens and coordinates, we'd love to meet you. Subscribe, share this episode with someone who needs a steady healthcare home, and leave a review to help more people discover whole-person primary care in Lynchburg.For more content from Centra Health check us out on the following channels.YouTubeFacebookInstagramTwitter

Join host Dr. Nikolaos Papadantonakis as he welcomes Dr. Colin Vale from Winship Cancer Institute of Emory University and Dr. Nancy Luna Torres from Moffitt Cancer Center to discuss the fundamentals of allogeneic hematopoietic stem cell transplantation for MDS patients.  Our experts break down complex medical concepts into easy-to-understand language, helping patients make informed decisions about this important treatment option.

In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential ThrombocythemiaAbstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MFAbstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDSAbstract 490: IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDSAbstract 487: Randomized Phase II Trial of Reduced Treatment Durations of Hypomethylating Agents for Lower-Risk MDSPresenter: Rami Komrokji, MDSenior Member, Vice ChairSection Head – Leukemia and MDSDepartment of Malignant HematologyH. Lee Moffitt Cancer CenterProfessor of Oncologic SciencesUniversity of South FloridaTampa, FloridaContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program: https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Émission originellement diffusée en juillet 2023.Connaissez-vous notre site ? www.lenouvelespritpublic.frUne émission de Philippe Meyer, enregistrée au studio l'Arrière-boutique le 9 juin 2023.Avec cette semaine :- Yves Plasseraud, juriste et spécialiste des États baltes.- Nicolas Baverez, essayiste et avocat.- François Bujon de l'Estang, ambassadeur de France.- Michel Eltchaninoff, rédacteur en chef du mensuel Philosophie Magazine.LES PAYS BALTESYves Plasseraud, vous êtes juriste et présidez depuis 1996 le Groupement pour le droit des minorités, ONG qui bénéficie d'un statut consultatif auprès des Nations unies, de l'Union européenne et du Conseil de l'Europe. Vous êtes un spécialiste des pays baltes et avez récemment publié deux ouvrages sur cette région du monde, qui regroupe l'Estonie, la Lettonie et la Lituanie. Dans Les pays baltiques - Le pluriculturalisme en héritage, paru en 2020, vous montrez comment l'histoire de ces pays est marquée par la menace constante de puissances impériales comme l'Allemagne ou la Russie, ainsi que par la diversité de leurs peuples et de leurs cultures. Vous avez également consacré, en 2022, un ouvrage aux peuples Germano-Baltes, nés au XIII° siècle des migrations de colons allemands à Riga, l'actuelle capitale de la Lettonie.Les pays baltes regroupent aujourd'hui plus de 6 millions d'habitants et représentent un PIB d'approximativement 120 Mds€. Bordés par la mer Baltique à l'ouest, ils s'étendent sur 175 000 km2 et partagent leurs frontières avec la Russie, la Biélorussie et la Pologne. A mi-chemin entre la Russie et l'Europe de l'Ouest, ils constituent une interface stratégique entre l'Orient et l'Occident, au cœur des enjeux géopolitiques et militaires contemporains.L'héritage soviétique pèse lourd dans ces anciennes Républiques socialistes soviétiques, territoire convoité par la Russie depuis Pierre le Grand pour son ouverture sur la mer Baltique. Avant l'invasion de l'Ukraine, la Fédération de Russie était l'un des principaux partenaires commerciaux de la région. Il lui fournissait également l'essentiel de son approvisionnement en gaz naturel, à hauteur de 42% en Lituanie, de 93% en Estonie et 100% en Lettonie. Les russophones constituent une importante minorité au sein des Pays Baltes et représentent jusqu'à 30% de la population en Lettonie. La mémoire de l'annexion russe, enfin, reste problématique, comme l'illustre la récente loi sur la destruction des monuments soviétiques promulguées par l'Estonie en début d'année.Pour se prémunir des menaces russes, les pays baltes ont choisi l'ancrage à l'Ouest. Ils ont adhéré à l'Union européenne en 2004, marquant la réussite de la transition démocratique et économique accomplie depuis 1991. La même année, les États baltes rejoignent l'OTAN. L'Alliance implante dès 2008 son centre de cyberdéfense à Tallin, à la suite de la cyberattaque de l'Estonie dirigée par le Kremlin une année auparavant. A la suite du sommet de 2016, à Varsovie, des troupes permanentes sont déployées par l'OTAN dans les Pays baltes dès 2017, ainsi que des forces navales et aériennes en mer Baltique.L'invasion de l'Ukraine par la Russie projette les Pays Baltes au cœur des enjeux de défense du monde occidental. Ces États, qui ont mis en garde l'UE contre la menace russe dès 2004, s'inquiètent d'être les prochaines cibles de Vladimir Poutine. Le corridor de Suwalki, qui permet aux Russes de desservir leur enclave européenne de Kaliningrad par la Biélorussie et comporte depuis 2016 des batteries de missile à capacité nucléaire, est au centre des tensions. Une crise avait même éclaté en juin 2022, à la suite de la décision de la Lituanie de restreindre le transit de marchandises par voie ferrée vers l'enclave russe, en accord avec les sanctions européennes. Dans ce contexte explosif, le prochain sommet de l'OTAN se tiendra en juillet à Vilnius, capitale de la Lituanie. Il y sera notamment question de la mise en place de nouveaux plans de défense pour la région baltique, mais aussi de l'adhésion de la Suède, candidate fortement soutenue par les Etats baltes.Chaque semaine, Philippe Meyer anime une conversation d'analyse politique, argumentée et courtoise, sur des thèmes nationaux et internationaux liés à l'actualité. Pour en savoir plus : www.lenouvelespritpublic.frHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Plusieurs débats au cœur de l'actualité, les Grandes gueules ont le choix, en débattre ou non : Corruption, Dati perquisitionnée par la Justice ; Mis en examen pour viols, Gérard Miller autorisé à voyager ; +70 MDS, la dette publique française a encore augmenté !

Send us a text if you want to be on the Podcast & explain why!Checkout Cody on IG: CodyMayFitWant to see how one trainer turned a free session into a $200K plan and a corporate wellness blueprint that wins boardrooms? We walk through the exact steps: earn trust with results, capture the data that matters, and translate those outcomes into clear ROI that executives can't ignore. Sick days down, blood pressure down, low back injuries down—when the metrics move, pricing power follows.Cody breaks down the shift from coach to operator: how referrals compounded into a book of business, why he attends seminars to sharpen skills, and what changed when he started hiring in his own name. We get specific about standards. Resumes stacked with acronyms are easy; applying anatomy, progressing programs, and defending your choices under pressure is what counts. You'll hear how a practical interview works with a real client, what professionalism looks like on the phone and on the floor, and why protecting the brand requires a high bar for every coach who touches a client.We also map the scalable play: launch a corporate wellness pilot with a tight intake—vitals, grip strength, movement, injury history, and strength benchmarks—then deliver a year of consistent coaching and report the outcomes in dollars saved. That proof of concept unlocks enterprise contracts and fuels a one-stop model that brings trainers, physical therapists, registered dietitians, and concierge MDs under one roof. Community grows, care improves, and the business becomes repeatable across locations.If you're serious about leveling up, this conversation is your checklist: set standards, document outcomes, build a team, and package your wins so decision makers can say yes. Enjoy the episode, share it with someone who needs a push, and if it helped you, subscribe and leave a quick review—it makes a real difference.Want to become a SUCCESSFUL personal trainer? SUF-CPT is the FASTEST growing personal training certification in the world! Want to ask us a question? Email info@showupfitness.com with the subject line PODCAST QUESTION to get your question answered live on the show! Website: https://www.showupfitness.com/Become a Successful Personal Trainer Book Vol. 2 (Amazon): https://a.co/d/1aoRnqANASM / ACE / ISSA study guide: https://www.showupfitness.com

No Café PT desta segunda-feira, Quenes Payayá, coordenadora do Setorial Nacional de Assuntos Indígenas do PT e consultora da Secretaria Nacional de Cuidado e Família do MDS, analisou a aprovação do Marco Temporal no Senado, uma decisão que contraria o STF e ameaça direitos constitucionais dos povos indígenas.

To celebrate the 40th Anniversay of the MDS, Dr. Michele Matarazzo sits down with two key leaders of the MDS Asian Oceanian section, Prof. Carolyn Sue and Prof. Beomseok Jeon. Together they discuss the early years of movement disorder “rock stars”, how the society has changed through their eyes, and impacts it has had on their careers.

To celebrate the 40th Anniversary of the MDS, Dr. Michele Matarazzo sits down with two key leaders of the MDS Pan-American section, Dr. Cynthia Comella and Dr. Oscar Gershanik. Together they discuss how they got involved in the society, what they are most proud of, and what the Society means to them, both professionally and personally.

Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, describes the development of bexmarilimad, a novel first-in-class immunotherapy that, unlike existing checkpoint inhibitors targeting T cells, targets the Clever 1 receptor on macrophages. This treatment is designed to reprogram the tumor microenvironment by switching marcophages from suppressive to active, enabling the patient's immune system to recognize and attack cancer cells. The primary disease target is higher-risk Myelodysplastic syndromes because the cancer cells in virtually all MDS patients express the Clever 1 target. Petri explains, "We are developing a completely new type of treatment. Currently, cancer patients are treated with immunotherapies called checkpoint inhibitors that target immune checkpoints. But our approach is targeting completely different cells, not T cells, but rather macrophages. And that's why we are first in class with a novel mode of action. And that's why it's important that these macrophages are shown to, for example, contribute to treatment resistance in many tumors." "Clever 1 actually is a receptor that was identified about 20 years ago. It found a certain macrophage as well as myeloid cells. And Clever 1 keeps the immune system in a tolerant and suppressive state. In cancer, for example, these Clever 1-positive macrophages essentially help the malignancy grow instead of helping to fight against it. And then our approach is that we want to block Clever 1 with our monoclonal antibody, bexmarilimab. So those macrophages switch the phenotype into an active antigen, preventing a pro-inflammatory state, and this reawakens immune surveillance. It allows T cells in the system to actually recognize the malignant cells themselves as dangerous and mount a proper antitumor response. So, a completely new mode of action by targeting Clever 1, we are not just adding another cytotoxic mechanism. We are removing the immune break and enabling the patient's own immune system to do the job that it was originally designed to do."  #FaronPharmaceuticals #BloodCancer #MDS #MyelodysplasticSyndrome #HR-MDS #CancerResearch #novelimmunotherapy #Bexmarilimab #Clever1 faron.com Download the transcript here

Dr. Petri Bono, Chief Medical Officer at Faron Pharmaceuticals, describes the development of bexmarilimad, a novel first-in-class immunotherapy that, unlike existing checkpoint inhibitors targeting T cells, targets the Clever 1 receptor on macrophages. This treatment is designed to reprogram the tumor microenvironment by switching marcophages from suppressive to active, enabling the patient's immune system to recognize and attack cancer cells. The primary disease target is higher-risk Myelodysplastic syndromes because the cancer cells in virtually all MDS patients express the Clever 1 target. Petri explains, "We are developing a completely new type of treatment. Currently, cancer patients are treated with immunotherapies called checkpoint inhibitors that target immune checkpoints. But our approach is targeting completely different cells, not T cells, but rather macrophages. And that's why we are first in class with a novel mode of action. And that's why it's important that these macrophages are shown to, for example, contribute to treatment resistance in many tumors." "Clever 1 actually is a receptor that was identified about 20 years ago. It found a certain macrophage as well as myeloid cells. And Clever 1 keeps the immune system in a tolerant and suppressive state. In cancer, for example, these Clever 1-positive macrophages essentially help the malignancy grow instead of helping to fight against it. And then our approach is that we want to block Clever 1 with our monoclonal antibody, bexmarilimab. So those macrophages switch the phenotype into an active antigen, preventing a pro-inflammatory state, and this reawakens immune surveillance. It allows T cells in the system to actually recognize the malignant cells themselves as dangerous and mount a proper antitumor response. So, a completely new mode of action by targeting Clever 1, we are not just adding another cytotoxic mechanism. We are removing the immune break and enabling the patient's own immune system to do the job that it was originally designed to do."  #FaronPharmaceuticals #BloodCancer #MDS #MyelodysplasticSyndrome #HR-MDS #CancerResearch #novelimmunotherapy #Bexmarilimab #Clever1 faron.com Listen to the podcast here

I've probably learned more about visual design from MDS than anyone in the design community.So I wanted to go deep into the creative process behind the all-new Shift Nudge website to see how he explores visual ideas.He takes us through his Figma file that is full of very good ideas that didn't ship.And he even shows us how he built his own Mosaic tool in v0 which became the core motif of the site.So if you're interested in seeing the windy creative process behind one of the truly great designers today then I think you're going to enjoy this one.

To celebrate the 40th Anniversay of the MDS, Dr. Sara Schaefer sits down with two key leaders of the MDS African Regional section, Dr. Njideka Okubadejo and Dr. Jonathan Carr. Together they discuss their experiences within MDS and what makes them proud to be long-standing members.

To celebrate the 40th Anniversay of the MDS, Dr. Sara Schaefer sits down with two key leaders of the MDS European Regional Section, Prof. Marie Vidailhet and Prof. Alberto Albanese. Listen as they share their fond memories of scholarly debate, Congress experiences, and hopes for the future.

EXCLUSIVE LIMITED TIME Just for My followers:From now until December 1st you can usecode: Daniel for 50% OFFJoin Dr. Glidden's Membership site: https://leavebigpharmabehind.com/?via=pgndhealth⁠For the already marked down annual membership to Dr GLIDDEN's health maintenance and education website. Make Dr. Glidden Your Doctor before Dec 1st and lock it in for life at only 55 cents a day!Code: Daniel for 50% OFF AnnualThe annual code discount brings the membership down to 55 cents a day, or 16.67/mo. This is the most affordable the membership has been EVER! Get locked in at the very BEST rate ever!Get Dr Monzo's Whole Food Supplements for your 90 Essential Revitalizing Nutrientswith code BB5 here: https://SemperFryLLC.comClick His Picture on the Right for the AZURE WELL products and use code BB5 for your discount.Find clickable portals to Dr Monzo and Dr Glidden on Dan's site, and it's the home of the best hot sauce, his book, and Clean Source Creatine-HCL.Get Dr Monzo's Whole Food Supplements for your 90 Essential Revitalizing Nutrients here: https://SemperFryLLC.comClick His Picture on the Right for the AZURE WELL products and use code BB5 for your discount.Become a supporter of this podcast: https://www.spreaker.com/podcast/ba-al-busters-broadcast--5100262/support.

Beyond the MD: Why a Johns Hopkins MBA Chose Medical Sales U (ft. Dr. Kevin Maggisano)What does it take to bridge the gap between clinical expertise and business execution? In this episode, we sit down with Dr. Kevin Maggisano, a professional who embodies the intersection of high-level medical vision and elite business strategy.Despite earning his MD from Western University and completing an MBA from Johns Hopkins, Dr. Maggisano believes that real leadership requires more than just degrees. It requires business clarity and strategic communication. That is exactly why he chose to enroll in Medical Sales U.In this episode, we cover:The Power of Continuous Growth: Why Dr. Maggisano believes leaders at every level, even those with MDs and MBAs, can still sharpen their business strategy and grow.Strategic Communication: How to move beyond clinical knowledge to master the art of communicating value and driving measurable results.Validating the Process: How Dr. Maggisano's experience reinforces the credibility and direction of Medical Sales U, proving that our focus on leadership and results works for top-tier professionals.Building a Career: Insights on how to build a rewarding career inside the medical sales world by combining medical authority with sales acumen.Dr. Maggisano's story is a powerful reminder that future leaders can trust the process. His voice amplifies our mission to help professionals identify their strengths and succeed in the competitive world of medical sales.About Dr. Kevin Maggisano: Dr. Maggisano combines deep medical insight with rigorous business training. He holds an MD from Western University and an MBA from Johns Hopkins University. He joined Medical Sales U to further strengthen his leadership skills and refine his approach to business strategy.Learn more about coaching and career support at https://medicalsalesu.com/

In this episode of Heart to Heart with HealthCap, Angie Szumlinski sits down with Jane Schoof, Director of Utilization at Atrium Living Centers, to discuss the most significant changes to the MDS 3.0 RAI Manual (v1.20.1), focusing on falls and injuries. Together, they review how CMS has redefined what constitutes a fall, including incidents caused by "overwhelming external forces," and explain what should now be coded as an intercepted fall. The discussion sheds light on how these updates are designed to close reporting gaps between hospital claims and MDS coding, improve accuracy, and strengthen resident care. Jane also provides insight into the revised definitions of major injury and injury except major, sharing how clinicians can apply clinical judgment, documentation, and teamwork to code consistently. The conversation emphasizes the importance of clearly documenting every fall, whether it occurs in therapy or during routine care, to ensure coding accuracy and regulatory compliance. To help you implement these new standards, HealthCap has created two companion resources: the Comprehensive Reference Guide: Understanding the 2025 MDS 3.0 Changes and the Falls and Injuries Quick Reference Handout. Both documents offer examples, practical tips, and operational insights to help your community align its coding and training practices with the 2025 updates.

Scrubs and Subpoenas: Nursing Scope of Practice - A $150 Million Mistake Part 1 SUMMARY: Scrubs and Subpoenas: Nursing Scope of Practice is a podcast series that explores the critical role of nursing scope of practice in ensuring patient safety and reducing malpractice claims. Through real-life malpractice cases, this series provides insights into the boundaries of nursing responsibilities, the consequences of exceeding or neglecting these boundaries, and actionable strategies to align practice with legal and ethical standards. Each episode serves as a cautionary tale and a guide to fostering accountability, transparency, and excellence in nursing care.        In this episode, we dive into the largest malpractice case ever filed against a nurse practitioner. This story begins with a young family NP working alone in a rural, four bed emergency room, caring for a patient rushed in after a syncopal event and a subsequent head injury sustained in the ER. Lack of resources and ineffective protocol blocked proper care for this patient, leading to a catastrophic pulmonary embolism. We dive into the incongruence of court protections for NPs vs. MDs, and the detrimental implications of restrictive practice scopes. Explore the connections between healthcare deserts and poor patient outcomes, and where NPs fit into this complex puzzle.  ---Nurses may be able to complete an accredited CE activity featuring content from this podcast and earn CE hours provided from Elite Learning by Colibri Healthcare. For more information, click hereAlready an Elite Member? Login hereLearn more about CE Podcasts from Elite Learning by Colibri HealthcareView this podcast course on Elite LearningSeries: Scrubs and Subpoenas: Nursing Scope of Practice

Scrubs and Subpoenas: Nursing Scope of Practice - A $150 Million Mistake Part 2  SUMMARY: Scrubs and Subpoenas: Nursing Scope of Practice is a podcast series that explores the critical role of nursing scope of practice in ensuring patient safety and reducing malpractice claims. Through real-life malpractice cases, this series provides insights into the boundaries of nursing responsibilities, the consequences of exceeding or neglecting these boundaries, and actionable strategies to align practice with legal and ethical standards. Each episode serves as a cautionary tale and a guide to fostering accountability, transparency, and excellence in nursing care.        In this episode, we dive into the largest malpractice case ever filed against a nurse practitioner. This story begins with a young family NP working alone in a rural, four bed emergency room, caring for a patient rushed in after a syncopal event and a subsequent head injury sustained in the ER. Lack of resources and ineffective protocol blocked proper care for this patient, leading to a catastrophic pulmonary embolism. We dive into the incongruence of court protections for NPs vs. MDs, and the detrimental implications of restrictive practice scopes. Explore the connections between healthcare deserts and poor patient outcomes, and where NPs fit into this complex puzzle. ---Nurses may be able to complete an accredited CE activity featuring content from this podcast and earn CE hours provided from Elite Learning by Colibri Healthcare. For more information, click hereAlready an Elite Member? Login hereLearn more about CE Podcasts from Elite Learning by Colibri HealthcareView this podcast course on Elite LearningSeries: Scrubs and Subpoenas: Nursing Scope of Practice

Ladies and gentlemen, welcome to another episode of the Cha Cha Album Review Series on the Cha Cha Music Review Podcast, my name is Hafeestonova, Your Musical plug, the Creator of the Energy Force and the African Music Amplifier.In today's episode I will talking about Burna Boy's album titled No Sign of WeaknessPress the Play Button to listen Artist: Burna BoyAlbum: No Sign of WeaknessFeatured Artist: Travis Scott, Mick Jagger, Stromae, ShaboozeyProducers: P2J, OTIS, Telz, Dre SkullMajor Seven, Niph Keys, Mds, Stromae, Jay SynthsYear: 10th of July, 2025Tracks: 16 tracksAlbum Link: https://open.spotify.com/album/2fXaK76zsSLaAMwCyCqKQL?si=21c32888aa114d90

As more states transition to PDPM for Medicaid, therapy is no longer the primary driver of case mix index (CMI). So where do providers turn next?In this episode, Melissa Brown, COO of Gravity Healthcare Consulting, sits down with Dr. Rehan Shah, nephrologist and co-founder of CardioRenal Vision (CRV), to explore how cardiology, nephrology, and pulmonology services can transform PDPM Medicaid outcomes.Together, they discuss:Why therapy-driven CMIs are declining under PDPM MedicaidHow specialty physician programs improve documentation, acuity capture, and reimbursement accuracyThe power of on-site care models—from dialysis to respiratory therapy—to reduce hospitalizations and boost CMIPractical steps for aligning physicians, MDS coordinators, and facility leadershipIf your organization is preparing for PDPM Medicaid—or already navigating the transition—this episode offers actionable insights to help you strengthen performance, accuracy, and margins under the new model.

In this episoe we're talking about how to feel like a priority in your relationship... without slipping into overthinking, over‑analyzing every text, or feeling like you're “asking for too much.” This episode is for you if: • You know they care about you… but you can't always feel it • You find yourself checking for proof or reassurance • You are tired of being the one initiating, planning, or emotionally leading • Your brain does wind sprints when there's space or distance in the relationship • You're successful in every other area of life, but your nervous system goes ✨ feral✨ in love   Trust me, I've lived this. I went from anxiously attached (and chronically exhausted from managing the relationship in my head) to actually feeling chosen, safe, and prioritized in a secure partnership. And we're unpacking exactly how that shift happens today.

Vous aimez notre peau de caste ? Soutenez-nous ! https://www.lenouvelespritpublic.fr/abonnementUne émission de Philippe Meyer, enregistrée en public à l'École alsacienne le 2 novembre 2025.Avec cette semaine :Akram Belkaïd, journaliste au Monde diplomatique.Jean-Louis Bourlanges, essayiste, ancien président de la Commission des Affaires étrangères de l'Assemblée nationale.Antoine Foucher, consultant, spécialiste des questions sociales, auteur de Sortir du travail qui ne paie plus.Lucile Schmid, présidente de La Fabrique écologique et membre du comité de rédaction de la revue Esprit.BILAN DE L'EXAMEN DU PLFLes députés ont commencé le 24 octobre l'examen de la partie recettes du projet de loi de finances (PLF), à l'Assemblée nationale.Après les trois premiers jours de débat à l'Assemblée nationale, les députés ont dégradé d'environ 4 Mds d'€ l'équilibre de la copie initiale. Lundi, la hausse de 2 Mds d'€ de la surtaxe sur les bénéfices des grandes entreprises a été votée à l'initiative du gouvernement, mais contre son camp. Les députés ont également adopté une mesure plus favorable aux entreprises, en votant l'article 11 du PLF, qui prévoit de reprendre l'an prochain la baisse de la cotisation sur la valeur ajoutée des entreprises, dont l'exécutif souhaite la suppression progressive pour « soutenir la dynamique de réindustrialisation ». Mercredi, les députés ont continué à détricoter la copie budgétaire du gouvernement avec l'adoption de deux amendements déposés par LFI : l'un pour élargir le champ d'application de l'impôt minimum de 15% sur les bénéfices des multinationales, l'autre pour instaurer une taxe exceptionnelle sur les superdividendes. De son côté, le RN a fait adopter grâce à l'abstention de la gauche une taxe de 33% sur les rachats d'actions qui, selon lui, rapporterait 8 Mds d'€. Face à ces revers pour le gouvernement, le bloc central a dénoncédepuis mardi une « surenchère fiscale ». Vendredi, l'article 3 du projet de loi sur le budget : la taxation des holdings a été adoptée par 224 députés, contre 10. La gauche s'est abstenue. La taxe Zucman sur les très hauts patrimoines a été largement rejetée, ainsi que sa version allégée, malgré la pression du PS. Vendredi soir, les députés ont lesté le budget Lecornu près de 45Mds€ de taxes supplémentaires (notamment la taxation proportionnelle des multinationales : 25Mds€, l'extension de la taxe sur les rachats d'actions : 8Mds€, la surtaxe de l'Impôt sur les Sociétés : 6Mds€, et dans la nuit un impôt sur la fortune improductive ...) Le Premier ministre a annoncé de nouvelles discussions avec les différents groupes parlementaires durant ce week-end. Les débats reprendront lundi.Les députés arrêteront leurs discussions sur le PLF lundi soir, avant de s'attaquer au projet de loi de financement de la Sécurité sociale à partir de mardi. Après son vote, prévu le 12 novembre, les débats pourront reprendre sur les recettes de l'État, pour enchaîner sur la deuxième partie du PLF, concernant les dépenses. Les projets de loi de finances et de financement de la sécurité sociale doivent être adoptés avant le 31 décembre. Les délais sont serrés, entre promesse de ne pas recourir au 49-3 et débats sur la réforme des retraites.Chaque semaine, Philippe Meyer anime une conversation d'analyse politique, argumentée et courtoise, sur des thèmes nationaux et internationaux liés à l'actualité. Pour en savoir plus : www.lenouvelespritpublic.frHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

In this powerful Ask Dr. Tony episode, Dr. Tony Ebel addresses the recent wave of anti-chiropractic content flooding social media from conventional medical doctors. Rather than responding with anger, Dr. Tony offers a thoughtful, science-based perspective on why natural, neurologically-focused healthcare is exploding in popularity—and why some in the medical community feel threatened by it.Dr. Tony emphasizes that this isn't about "us versus them," but about giving families effective options. He shares his deep respect for emergency medicine (which saved his son Oliver's life) while making a compelling case for why drug-free, neurological approaches should be the first line of defense for chronic conditions. Throughout the episode, he dismantles common criticisms with updated neuroscience, real-world outcomes, and the principle that being effective matters more than being right.----Links & Resources:Listen to Oliver's Miracles Story Here.----Key Topics & Timestamps[00:01:00] - The Social Media Backlash: Dr. Tony addresses the recent flood of hateful, reactionary posts from MDs targeting chiropractors and natural health[00:03:00] - Straw Man Arguments Exposed: Breaking down how critics misrepresent what neurologically-focused chiropractors actually do [00:11:00] - Being Right vs. Being Effective: The real issue—are doctors focused on protecting their turf or serving families?[00:19:00] - Outcomes Over Opinions: Why we should compare real health results between conventionally-raised kids and those receiving neurological care[00:24:00] - Oliver's Story: Dr. Tony shares his personal gratitude for emergency medicine that saved his son's life[00:31:00] - The Nervous System Revolution: How modern neuroscience confirms what chiropractic has understood for 125+ years[00:38:00] - Medicine Saves Lives, Chiropractic Restores Lives: Defining the proper roles and sequencing of different healthcare approaches[00:42:00] - Understanding Before Criticizing: Why critics who never studied chiropractic can't accurately critique it[00:46:00] - Advice for Parents: How to handle the negativity and stay focused on what works for your family -- Follow us on Socials: Instagram: @pxdocs Facebook: Dr. Tony Ebel & The PX Docs Network Youtube: The PX Docs For more information, visit PXDocs.com to read informative articles about the power of Neurologically-Focused Chiropractic Care. Find a PX Doc Office near me: PX DOCS DirectoryTo watch Dr. Tony's 30 min Perfect Storm Webinar: Click HereSubscribe, share, and stay tuned for more incredible episodes unpacking the power of Nervous System focused care for children!

In nearly every conversation I have about growing old, the same three concerns surface. No one wants to be really old and sick. No one wants to be really old and lonely. And no one wants to be really old and broke.Curtis Estes is a wealth management advisor who has been helping high-achievers design lives of purpose and longevity since 1991, when he began his career with Northwestern Mutual. Based in West Los Angeles with his wife and three children, Curtis brings over three decades of experience guiding clients through financial strategies that support vibrant, extended living. A journalism graduate from the University of Kansas, he's authored five books that reflect his passion for intentional living and legacy building. Curtis has also built a longevity community to give participants access to the latest insights from MDs, PhDs and longevity tech CEOs. Connect with Curtis: www.curtisestes.com.To View This Episode- https://youtu.be/d9g4VhXYbOk#philfriedrich #whoknewinthemoment #author #financialfreedom #longevity

Did you know that premature ejaculation is the most common form of sexual dysfunction on the planet? In a similar vein, experts estimate that erectile dysfunction impacts a staggering 30-50 million men in the U.S. alone. And some studies suggest that 1 in 10 men experiences delayed ejaculation.The truth is, sexual dysfunction affects millions and millions of men, but the experience is often one of being alone. Helpless. Feeling stuck or out of control. Common thoughts:"Why can't I get hard when I want the sex? I feel like my body's betraying me.""I'm so frustrated about cumming so fast -- I want sex to last.""What's the point of even going on a date if I know it's eventually gonna end up in the bedroom?""I'm terrified that I won't satisfy her sexually, and then she'll either humiliate me, leave me, or both.""What's wrong with me?"---Here, Luke reveals the one primary and often overlooked yet vitally important commonality that exists between all sexual dysfunction. As he puts it, “Western medicine has reduced it to it being all about blood flow...” and it's about way more than that.As a doctor of Chinese medicine, Luke brings a unique and potent perspective on the topic. The plain truth is that overcoming sexual dysfunction like erectile dysfunction, premature ejaculation, and delayed ejaculation is simply not about what you think it's about.---Work with usReady to go deeper than the podcast and take action? Jason and I can help you break old patterns and transform your sex & love life for good. To see if you're a fit for our flagship program, Pillars of Presence, book a call here. Start anytime. (https://evolutionary.men/apply/)---Memorable quotes:“I have to whisper about it in doctor's offices.""Shoutout to the men for whom Viagra or Cialis just don't work."“Men are conditioned, programmed, indoctrinated into carrying their pain alone."“I went to naturopaths and MDs and nothing touched it.”“I get that you can run 100 miles. Let's talk about your relationships.”“I could not RECEIVE help … like it could not get into my body.”“Your cock is your compass.”“This isn't about sex; this is about power.”“It's literally a miracle.”---Mentioned on this episode:Luke Adler: https://lukeadlerhealing.com/To book a call with me to discuss Sexual Mastery, just email me at dearmenpodcast at gmail dot com

MDs have main character energy, but don't ignore Physician Assistants. We talk a lot about medical students on this podcast, but at Iowa we also have a physician assistant program, one that's very well regarded, nationally. So to kick off national PA Week, we've got a bunch of PA students to talk about their profession. PA2s Emily Mazzeo and Abby Crow, and PA1s David Walker Hofbauer and Jake Groh talk about what it's like to study alongside MD students (something unique to Iowa), how they view their place in healthcare, how they knew they wanted to be a PA, and where they see their profession heading in the next few years. Hint: their profession is the 10th fastest-growing career in the US, with an enviable work-life balance, more mobility than MDs, and similar opportunities to specialize or go into primary care. BTW, you can find out more about the PA career, as well as the MD and biomedical science PhD programs, at our virtual conference next week! Episode credits: Producer: Emily Mazzeo and Abby Crow Co-hosts: Emily Mazzeo, Abby Crow, David Walker Hofbauer, Jake Groh We Want to Hear From You: YOUR VOICE MATTERS! We welcome your feedback, listener questions, and shower thoughts. Do you agree or disagree with something we said today? Did you hear something really helpful? Can we answer a question for you? Are we delivering a podcast you want to keep listening to? Let us know at https://theshortcoat.com/tellus and we'll put your message in a future episode. Or email theshortcoats@gmail.com. We need to know more about you! https://surveys.blubrry.com/theshortcoat (email a screenshot of the confirmation screen to

Dave Rubin of “The Rubin Report” talks to Jillian Michaels about society's obsession with youth and cosmetic procedures; the importance of healthspan over lifespan; the dangers of extreme anti-aging therapies like stem cells and peptides; the risks wealthy individuals face with unproven treatments; how to vet fitness and longevity advice in a world of conflicting health information and online influencers; why she defers to MDs and PhDs over internet trends; her decision to avoid metformin and methylene blue; and how she overcame severe back pain through rehab and smart spine care; cognitive decline in the modern world; how processed food and endless information may be aging our brains faster than in past generations; why diet, genetics, and neuroprotective habits matter; how media bias suppresses legitimate questions about vaccine safety; the importance of critical thinking around public health policies; the role of Big Pharma funding in mainstream media narratives; media bias and truth in podcasting; how influencers should take personal responsibility when discussing complex topics; the lack of transparency around the hepatitis B vaccine and its potential risks; how lobbying by Big Pharma shaped vaccine mandates; how she would handle vaccinating her kids based on disease risk; and the need for people to research for themselves, especially on childhood immunizations; and much more.